BlueStar, the First Prescription-Only App

Doctors start prescribing the BlueStar app for diabetes management

3 min read
Illustration: Greg Mably

This year, when patients throughout the United States begin downloading the world’s first doctor-prescribed smartphone app, mobile health care will finally get what big-time medicine most requires: a way to get insurance companies to pay for it.

The app, called BlueStar, helps people with Type 2 diabetes (the most common kind) by suggesting, in real time, when to test their blood sugar and how to control it by varying medication, food, and exercise. That it requires a physician’s prescription is actually an advantage, because it means insurance companies will reimburse BlueStar’s fee.

“This is a piece of software getting the same treatment as a medical device,” says Sonny Vu, cofounder of Misfit Wearables in San Francisco, a maker of wearable computing devices. “It’s pretty world-changing.”

The U.S. Food and Drug Administration cleared BlueStar for market in 2010, in line with its recent determination to regulate devices that provide a diagnosis or recommend a treatment, not those that simply track activity, like calories consumed or steps taken. The success that WellDoc, the app’s manufacturer, has had with the FDA may inspire other mobile health companies to go the regulatory route. “It gives us hope that you can pull something like this off,” says Vu. The European Commission has also issued guidance on regulations for mobile health apps, but countries such as China and India have not.

WellDoc, based in Baltimore, began a regional launch last fall and plans to do a national push in 2014. The success of the app hinges on how many physicians prescribe it. “[WellDoc] will have to convince providers that it’s valuable,” says Athena Philis-Tsimikas, corporate vice president at the Scripps Whittier Diabetes Institute in San Diego.

The app addresses one of the toughest tasks a physician has: changing patient behavior. Doctors ask diabetic patients to keep a daily record of glucose readings, food, exercise, and medications. If managed well, these factors keep patients’ blood sugar in a safe range, reducing their risk of complications from the disease. But only 15 to 20 percent of patients actually keep a log, says Philis-Tsimikas. Diabetes apps that make activity tracking easier are available, but their effectiveness is limited. “No one does it, because you have to wait 90 days before you get feedback [at your next doctor visit],” says Richard Katz, who has studied mobile health at George Washington University, in Washington, D.C.

BlueStar’s developers say that’s where their product shines. BlueStar gives patients real-time feedback and customized coaching “in bite-sized pieces,” says Chris Bergstrom, chief strategy and commercial officer at WellDoc. Some messages are motivational (“Great job!”), some are educational (“Your medication works best if you take it with a meal”), and some suggest action (“You should take eight units of insulin right now”). Any coaching related to the patient’s medicine will coincide with the doctor’s prescribed plan. The app, which works on Android and iPhone platforms and on tablets and computers, also sends regular data updates to the patient’s physician, along with suggestions on changes to the treatment regimen.

In a 2011 clinical study at the University of Maryland School of Medicine, BlueStar helped people with diabetes reduce their hemoglobin A1C, a key measure of blood sugar control. Researchers observed that blood levels of A1C dropped by 1.9 percentage points in the treatment group compared with a 0.7 percentage point reduction in a control group. That much of an improvement is extraordinary, say endocrinologists. “This is more effective than the medications we can prescribe,” says Amit Rajvanshi, a family physician in Rockville, Md., whose patients participated in the study.

Vu says BlueStar is most likely the first of many prescription-only apps, although he doesn’t know of any in development that have been publicly announced. “There might be a handful more this year and more next year, but due to regulatory and reimbursement timelines, I don't think there will be an avalanche right away,” he says. WellDoc, for its part, is developing prescription apps for other, undisclosed diseases. Sooner or later, those FDA reviewers are likely to have their hands full.

The Conversation (0)

How Efficient Is Your EV? It’s Complicated

Some day, charging an EV is going to be a lot more interesting

3 min read
PITINAN PIYAVATIN/ALAMY

With motor sports moving hard and fast toward electric drive, a friend recently told me that electric drag-car racing just wouldn't be the same without the deafening roar of combustion engines and the smell of "nitro" fuel.

She's 90 years old. I didn't feel like arguing with her.

Keep Reading ↓ Show less

How Robots Helped Out After the Surfside Condo Collapse

Responders flew drones night and day to survey the collapse and search for survivors

10 min read

Image of the collapse from a drone on July 2, 2021.

Robin R. Murphy

Editor's Note: Along with Robin Murphy, the authors of this article include David Merrick, Justin Adams, Jarrett Broder, Austin Bush, Laura Hart, and Rayne Hawkins. This team is with the Florida State University's Disaster Incident Response Team, which was in Surfside for 24 days at the request of Florida US&R Task 1 (Miami Dade Fire Rescue Department).

On June 24, 2021, at 1:25AM portions of the 12 story Champlain Towers South condominium in Surfside, Florida collapsed, killing 98 people and injuring 11, making it the third largest fatal collapse in US history. The life-saving and mitigation Response Phase, the phase where responders from local, state, and federal agencies searched for survivors, spanned June 24 to July 7, 2021. This article summarizes what is known about the use of robots at Champlain Towers South, and offers insights into challenges for unmanned systems.

Keep Reading ↓ Show less

Stevens Engineers Design Fetal Heart Monitor That Could Detect Early Signs of Pregnancy Complications

Gyroscopes and accelerometers inside fingernail-sized devices accurately monitor fetal heart rate and movements without electrode attachments, even when worn over clothing

3 min read
Stevens Institute of Technology

A baby's heartbeat can be detected as early as six weeks into pregnancy. From around 12 weeks until birth, doctors will listen to the fetus' heartbeat at every prenatal appointment to closely monitor the baby's health. But what if fetal heart activity changes in between these appointments, while the doctor isn't there to listen? Engineers at Stevens Institute of Technology have designed a wearable device that continuously monitors fetal activity—even from home—in order to detect early signs of complications and allow for prompt, potentially life-saving interventions.

“If we can monitor fetal heart rate continuously, when the mother is sleeping and so forth, there may be signs that show complications," said Negar Tavassolian, assistant professor of electrical and computer engineering who is leading this research at the Schaefer School of Engineering and Science. “We can recognize these signs ahead of time and warn the mother to go see the doctor, whereas if she just relies on the doctor's visits alone, then a lot of things can go wrong in between."

Keep Reading ↓ Show less

Trending Stories

The most-read stories on IEEE Spectrum right now